Jump to content

Recommended Posts

Posted
4 minutes ago, aggie08 said:

Can you just not be a disingenuous cunt for, like, 3 seconds?

  

31 minutes ago, Anastasis said:

mRNA tech needs to be kept in the stable, the rapid response capability is important. But it has not proven out to be a particularly durable solution. We need sterilizing vaccines, IgA eliciting nasally administered vaccines, and traditional subunit protein vaccines to round out. Everyone should now be basically transitioning to novavax for covid until a nasally administered sterilizing vaccine comes to market. Shifting the research dollars is appropriate, but mRNA needs to be kept in the back pocket. 

 

  • Fuck You 1
Posted
Just now, HenryJames said:

Big Beautiful Vaccine

Jesus tapdancing Christ.  Noted highly trained and experienced virologist RFK Jr....wait, what's that, he has literally ZERO formal training or qualifications in the field?  Well, anyway, the world's most respected and highly trained virologist, RFK Jr, is leading the charge to create an...."everything vaccine."

Will this "vaccine," which will "mimic natural immunity" (whatever the fuck THAT means in his sponge brain) be available for online purchase, pursuant to ads on right-wing podcasts and such?  You bet your ass.

Will it work?  Highly doubtful, being that its chief promoter doesn't even think infectious diseases are much of a thing: “I do not believe that infectious disease is an enormous threat to human health."  Those are his exact words, from way back....just two fucking years ago.

Someone turned this timeline to max stupidity, then snapped the knob off to just let it run at redline.

  • Hook 'Em 4
  • Fuck Around and Find Out 1
Posted

This is what’s being referred to clumsily and imprecisely in that clip. Yet to be seen if they can land it. 
 

https://www.nih.gov/news-events/news-releases/hhs-nih-launch-next-generation-universal-vaccine-platform-pandemic-prone-viruses

Thursday, May 1, 2025

HHS, NIH launch next-generation universal vaccine platform for pandemic-prone viruses

Image

Colorized transmission electron micrograph of influenza A/H1N1 virus particles. 

The U.S. Department of Health and Human Services (HHS) and the National Institutes for Health (NIH) today announced the development of the next-generation, universal vaccine platform, Generation Gold Standard, using a beta-propiolactone (BPL)-inactivated, whole-virus platform.

This initiative represents a decisive shift toward transparency, effectiveness, and comprehensive preparedness, funding the NIH’s in-house development of universal influenza and coronavirus vaccines, including candidates BPL-1357 and BPL-24910. These vaccines aim to provide broad-spectrum protection against multiple strains of pandemic-prone viruses such as H5N1 avian influenza and coronaviruses including SARS-CoV-2, SARS-CoV-1, and MERS-CoV.

“Our commitment is clear: every innovation in vaccine development must be grounded in gold standard science and transparency, and subjected to the highest standards of safety and efficacy testing,” said HHS Secretary Robert F. Kennedy, Jr.

The program realigns BARDA’s operations with its statutory mission under the Public Health Service Act—to prepare for all influenza viral threats, not just those currently circulating.

“Generation Gold Standard is a paradigm shift,” said NIH Director Dr. Jay Bhattacharya. “It extends vaccine protection beyond strain-specific limits and prepares for flu viral threats – not just today’s, but tomorrow’s as well – using traditional vaccine technology brought into the 21st century.”

Generation Gold Standard, developed exclusively by NIH’s National Institute of Allergy and Infectious Diseases (NIAID):

Recalibrates America’s pandemic preparedness. Unlike traditional vaccines that target specific strains, BPL-inactivated whole-virus vaccines preserve the virus’s structural integrity while eliminating infectivity. This approach induces robust B and T cell immune responses and offers long-lasting protection across diverse viral families. Moreover, the intranasal formulation of BPL-1357 is currently in Phase Ib and II/III trials and is designed to block virus transmission—an innovation absent from current flu and COVID-19 vaccines.

Embodies efficient, transparent, and government-led research. The BPL platform is fully government-owned and NIH-developed. This approach ensures radical transparency, public accountability, and freedom from commercial conflicts of interest.

Marks the future of vaccine development. In addition to influenza and coronavirus, the BPL platform is adaptable for future use against respiratory syncytial virus (RSV), metapneumovirus, and parainfluenza. It also offers the unprecedented capability to protect against avian influenza without inducing antigenic drift—a major step forward in proactive pandemic prevention.

Clinical trials for universal influenza vaccines are scheduled to begin in 2026, with Food and Drug Administration (FDA) approval targeted for 2029. The intranasal BPL-1357 flu vaccine, currently in advanced trials, is also on track for FDA review by 2029.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

  • Fuck You 1
Posted (edited)

I have concerns that this vaccine will include a nano chip for tracking and other purposes. 
 

but it is interesting to know that Kennedy and Trump are aware that government is better at handling these kinds of problems than private industry.  Is there a word for that one of thought?  

Edited by Pato del Muerto
Posted
34 minutes ago, Pato del Muerto said:

I have concerns that this vaccine will include a nano chip for tracking and other purposes. 
 

but it is interesting to know that Kennedy and Trump are aware that government is better at handling these kinds of problems than private industry.  Is there a word for that one of thought?  

no, see, this vaccine is being developed under trump so it definitely won't have 5g chips in it unlike those other vaccines which were developed under *checks notes* trump

  • Hook 'Em 2
  • Haha 1
Posted
This is what’s being referred to clumsily and imprecisely in that clip. Yet to be seen if they can land it. 
 
https://www.nih.gov/news-events/news-releases/hhs-nih-launch-next-generation-universal-vaccine-platform-pandemic-prone-viruses
Thursday, May 1, 2025
HHS, NIH launch next-generation universal vaccine platform for pandemic-prone viruses
Image
Colorized transmission electron micrograph of influenza A/H1N1 virus particles. 
The U.S. Department of Health and Human Services (HHS) and the National Institutes for Health (NIH) today announced the development of the next-generation, universal vaccine platform, Generation Gold Standard, using a beta-propiolactone (BPL)-inactivated, whole-virus platform.
This initiative represents a decisive shift toward transparency, effectiveness, and comprehensive preparedness, funding the NIH’s in-house development of universal influenza and coronavirus vaccines, including candidates BPL-1357 and BPL-24910. These vaccines aim to provide broad-spectrum protection against multiple strains of pandemic-prone viruses such as H5N1 avian influenza and coronaviruses including SARS-CoV-2, SARS-CoV-1, and MERS-CoV.
“Our commitment is clear: every innovation in vaccine development must be grounded in gold standard science and transparency, and subjected to the highest standards of safety and efficacy testing,” said HHS Secretary Robert F. Kennedy, Jr.
The program realigns BARDA’s operations with its statutory mission under the Public Health Service Act—to prepare for all influenza viral threats, not just those currently circulating.
“Generation Gold Standard is a paradigm shift,” said NIH Director Dr. Jay Bhattacharya. “It extends vaccine protection beyond strain-specific limits and prepares for flu viral threats – not just today’s, but tomorrow’s as well – using traditional vaccine technology brought into the 21st century.”
Generation Gold Standard, developed exclusively by NIH’s National Institute of Allergy and Infectious Diseases (NIAID):
Recalibrates America’s pandemic preparedness. Unlike traditional vaccines that target specific strains, BPL-inactivated whole-virus vaccines preserve the virus’s structural integrity while eliminating infectivity. This approach induces robust B and T cell immune responses and offers long-lasting protection across diverse viral families. Moreover, the intranasal formulation of BPL-1357 is currently in Phase Ib and II/III trials and is designed to block virus transmission—an innovation absent from current flu and COVID-19 vaccines.
Embodies efficient, transparent, and government-led research. The BPL platform is fully government-owned and NIH-developed. This approach ensures radical transparency, public accountability, and freedom from commercial conflicts of interest.
Marks the future of vaccine development. In addition to influenza and coronavirus, the BPL platform is adaptable for future use against respiratory syncytial virus (RSV), metapneumovirus, and parainfluenza. It also offers the unprecedented capability to protect against avian influenza without inducing antigenic drift—a major step forward in proactive pandemic prevention.
Clinical trials for universal influenza vaccines are scheduled to begin in 2026, with Food and Drug Administration (FDA) approval targeted for 2029. The intranasal BPL-1357 flu vaccine, currently in advanced trials, is also on track for FDA review by 2029.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

“Clumsily and imprecisely.”

I’m sure RFK deeply appreciates that you, without fail, have his back.
He wasn’t referring to illness-specific vaccines. That’s not what he said. He almost certainly doesn’t understand what he’s talking about, or what’s referenced above.
Remember, he thinks infectious diseases aren’t a real problem.
  • Drool 1
Posted
32 minutes ago, Brisketexan said:


“Clumsily and imprecisely.”

I’m sure RFK deeply appreciates that you, without fail, have his back.
He wasn’t referring to illness-specific vaccines. That’s not what he said. He almost certainly doesn’t understand what he’s talking about, or what’s referenced above.
Remember, he thinks infectious diseases aren’t a real problem.

I don’t think Rfk cares one way or another. People can read your post on this page and then read mine and assess which one they find more relevant and valuable to understanding what is taking place at nih. 

  • Fuck You 1

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.



×
×
  • Create New...